October 17, 2016
A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) will discuss adding relapsed or refractory classical Hodgkin’s lymphoma to Ono Pharmaceutical’s anti-PD-1 antibody Opdivo’s (nivolumab) indications at a meeting on October 27. If this indication is...read more